Business Context and Reporting Period
This Form 8-K was filed by SANUWAVE Health, Inc. on June 29, 2023, reporting events occurring on June 23, 2023, and June 26, 2023. The filing primarily addresses a material amendment to an existing debt agreement and a change in the company's officer status.
Key Financial Metrics and Debt Obligations
The filing details specific terms regarding the company's debt structure but does not provide current revenue, profit, or cash flow figures.
- Debt Amendment: Entered into a Fourth Amendment to the Note and Warrant Purchase and Security Agreement (NWPSA).
- Interest Rate: Deferred interest will be compounded and added to the principal, bearing interest at 20.25% per annum.
- Consent Fee: A non-refundable fee of 2% of the original principal amount of the notes is required, payable at maturity.
- Financing Covenant: The company must complete an equity financing resulting in gross cash proceeds of at least $2.5 million by July 15, 2023.
Material Changes and Corporate Actions
The following material changes were reported:
- Forbearance Extension: The agent and noteholder extended their forbearance of remedies arising from existing defaults until the earlier of an event of default or December 31, 2023.
- Interest Deferral: Interest payments originally due on June 30, 2023, and September 30, 2023, have been deferred and capitalized.
- Officer Status Change: Lisa Sundstrom, previously Chief Talent Officer and Secretary, was determined by the Board to no longer satisfy the definition of an "officer" or "executive officer" under the Exchange Act as of June 26, 2023.
Outlook, Risks, and Contingencies
The filing highlights significant liquidity and compliance risks:
- Existing Defaults: The company is currently operating under "Existing Defaults" as defined in the NWPSA, though remedies are temporarily forbore.
- Financing Requirement: There is a strict deadline (July 15, 2023) to raise $2.5 million in equity financing. Failure to meet this covenant could trigger an event of default.
- Increased Debt Burden: The compounding of deferred interest at a high rate (20.25%) increases the total principal obligation.
Investor Verification Checklist
- Verify the status of the required $2.5 million equity financing by the July 15, 2023 deadline.
- Confirm the total outstanding principal amount of the notes to calculate the 2% consent fee and capitalized interest.
- Review the full text of the Fourth Amendment (Exhibit 10.1) for specific definitions of "Existing Defaults" and potential triggers for an event of default.
- Assess the company's current liquidity position given the deferral of cash interest payments.